All articles tagged with #obesity
Regular movement is the most effective treatment for osteoarthritis, yet many patients aren’t referred to exercise or physiotherapy; supervised programs like GLA:D improve pain and function and can provide benefits for months. There are no disease-modifying drugs, and surgery is often considered only after non-surgical options fail, while obesity and inflammation influence risk but can be countered by ongoing activity.
Trinidad-born doctors Dr. Robert Jupiter and Dr. Karen Moses return to Trinidad and Tobago to launch Stellar Medical, a stigma-free clinic focused on obesity and metabolic health. They emphasize treating obesity as a chronic, biology-driven disease, discuss GLP-1/GIP meds like Wegovy, Ozempic, Zepbound and Mounjaro, but prioritize nutrition, movement, hydration, sleep, and mental wellbeing, and will collaborate with therapists when needed.
At the JPMorgan Healthcare Conference, Novo Nordisk signals 2026 will bring price pressure as GLP-1 supply grows and pricing deals take effect, even as it pushes the Wegovy oral pill and expands the incretin market. Bristol Myers Squibb projects up to 10 new products by 2030 to counter upcoming exclusivity losses, while Pfizer insists it is “all in on obesity” and plans multiple late‑stage obesity studies tied to Metsera. The conference also features news such as Lilly and Nvidia jointly funding an AI drug‑discovery lab and AbbVie striking a price‑reduction deal with the Trump administration plus a RemeGen cancer-therapy license.
New dietary guidelines include a section on testosterone health in men, noting that diet may modestly influence testosterone but the evidence is weak; recommendations emphasize healthy fats (avoiding very low-fat diets), potential DHA supplementation, zinc, and vitamin D, while cautioning against excessive protein. Weight loss in overweight men is linked to higher testosterone, though no single food will dramatically boost levels. Experts urge cautious interpretation and more research.
Oprah Winfrey reflects on decades of weight struggles, describing a biologically driven “enough point” and a shift from self-blame to a science-informed approach outlined in her book Enough with Dr. Ania Jastreboff. After resisting weight-loss medications for years due to shame, she started GLP-1–type drugs about two years ago, paired with daily hiking and resistance training, and now weighs about 155 pounds—the marathon weight—and says she feels healthier and stronger at 71 than at 40. Medical experts emphasize obesity as a treatable disease, not a personal fault, and Oprah’s openness aims to reduce stigma and encourage sustainable, health-focused strategies.
Research from Oxford indicates that stopping GLP-1 medications like Ozempic often results in weight regain within 18-24 months, highlighting obesity as a chronic condition requiring long-term management rather than short-term medication use.
Eli Lilly's Phase 3b trial shows that combining Taltz (ixekizumab) and Zepbound (tirzepatide) significantly improves outcomes in adults with psoriatic arthritis and obesity, meeting primary and secondary efficacy endpoints and suggesting a potential new integrated treatment approach.
U.S. Agriculture Secretary Brooke Rollins announced new dietary guidelines emphasizing whole foods, healthy fats, and reducing processed foods and sugars to combat obesity, marking a significant shift from previous recommendations and focusing on real, nutrient-dense foods.
A study from the University of Utah found that the gut bacteria Turicibacter can significantly reduce weight gain and improve metabolic health in mice on a high-fat diet, suggesting potential for microbiome-based therapies for obesity and related diseases in humans.
Arrowhead Pharmaceuticals' gene-silencing drug candidate ARO-INHBE, in combination with Eli Lilly's Zepbound, showed promising early results in reducing weight and harmful visceral fat in obese patients with diabetes, potentially intensifying competition in weight loss drug development.
Novo Nordisk has launched an oral version of its weight-loss drug Wegovy in the U.S., offering a convenient alternative to injections. The pill, containing semaglutide, was approved by the FDA in December and is available for $149 per month for initial doses, with prices increasing later in April. Clinical trials show significant weight loss benefits, making it a notable innovation in obesity treatment.
Americans can now access a daily pill form of Wegovy, a popular weight-loss drug, which is generally cheaper than the weekly injection and is available with a prescription. The pill contains the same active ingredient as the injection, semaglutide, and offers an alternative for those seeking weight management solutions, with pricing options and insurance savings programs. The FDA approved the oral version in late December, and it shows similar efficacy and side effects to the injectable form.
Novo Nordisk launches the first oral GLP-1 pill for weight loss in the U.S., offering a more affordable and accessible alternative to injections, with prices ranging from $149 to $299 per month, and aims to capture a significant share of the growing obesity treatment market.
Novo Nordisk's Wegovy® pill, the first oral GLP-1 medication for weight loss, is now widely available across US pharmacies and telehealth providers, offering an effective option for adults with obesity or overweight with medical issues, with an average weight loss of about 17% if all patients stay on treatment.
The article previews ten significant clinical trials expected in the first half of 2026, focusing on Eli Lilly's obesity drug retatrutide, Merck's flu antiviral CD388, Regenxbio's gene therapy for Duchenne muscular dystrophy, Novartis' Lp(a) cardiovascular treatment, and other innovative therapies for rare diseases and cardiovascular conditions. Success in these trials could lead to major advancements and market approvals in their respective fields.